Evidence map›Paper›PMID 35678123›Full record

ArticleThe Journal of urology2022

Acute Lower Back Pain after Intralesional Injection of Collagenase

John T Sigalos, Michelle K Li, Dar A Yoffe, Neilufar Modiri, Ming-Yeah Y Hu, Dyvon T Walker, Thomas W Gaither, Alvaro Santamaria, Keith V Regets, Sriram V Eleswarapu and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

John T SigalosDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.ORCID 0000-0001-9458-9626
Michelle K LiDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Dar A YoffeDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Neilufar ModiriDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Ming-Yeah Y HuDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Dyvon T WalkerDivision of Urology, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-5134-1118
Thomas W GaitherDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.ORCID 0000-0003-0451-8344
Alvaro SantamariaDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.ORCID 0000-0001-5330-0427
Keith V RegetsDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.ORCID 0000-0002-9563-4211
Sriram V EleswarapuDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.ORCID 0000-0003-1852-4833
Jesse N MillsDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.ORCID 0000-0002-7833-7071
University of California, Los Angeles · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe safety label for collagenase MATERIALS AND

methodsData on all men undergoing collagenase injections for Peyronie's disease at our institution from October 2015 through December 2020 were retrospectively assessed. The study included 330 patients, 300 completing at least 1 full course (8 injections). Measured outcomes included incidence and timing of back pain, and associations with demographics and comorbidities.

resultsOf 330 patients, 19 (5.8%) experienced at least 1 episode of postinjection acute lower back pain. Of 300 who completed at least 1 full course of 8 injections, 4 (1.3%) reported back pain within the 8-injection course. A subset underwent additional rounds (16 or 24 injections). Back pain increased to 8.7% (13/149) during a second round, 6.9% (3/43) during a third. No association was found with age, diabetes or back pain history. Most cases occurred shortly after injection; all were self-limited or resolved with a single dose of ketorolac.

conclusionsThis single-center, retrospective analysis suggests that intralesional collagenase injections for Peyronie's disease may cause acute lower back pain in up to 6% of patients. Patients may benefit from counseling regarding this risk. Incidence rises with additional rounds of treatment. Prospective safety data regarding >8 injections do not exist. No patient had long-term sequelae of back pain.

Indexed as

Low Back PainMicrobial CollagenasePenile IndurationHumansInjections, IntralesionalMaleProspective StudiesRetrospective StudiesTreatment OutcomeMicrobial Collagenaseback pain; injections, intralesionalmicrobial collagenasepenile induration

Identifiers

PMID35678123
PMCPMC12721609
OpenAlexW4282934520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.